Evaluation Of The Provision Of Single Use Citric Acid Sachets To ...

More documents

Recommendations

Info

23REFERENCESAustralian National Council on Drugs (2001). Needle and Syringe Programs. ANCD,CanberraBlumenthal, R. N., A. H. Kral, L. Geee, E. A. Erringer, & B. Edlin (2000). “The effect ofsyringe exchange use on high-risk injecting drug users: a cohort study.” AIDS 14: 605-611Buning, E. C. (1991). “Effects of Amsterdam needle exchange and syringe exchange.”Inte rna tiona l Journa l o f the Addictions 26:1303-1311Centers for Disease Control and Prevention (1993). The Public Health Impact of NeedleExchange Programs in the United States. University of California, San FransiscoCenters for Disease Control and Prevention (1997). “HIV-prevention bulletin for healthcareproviders regarding advice to persons who inject illicit drugs.” Morbidity and MortalityWeekly Report 46: 510Choo, Q. L., et al (1989). “Isolation of a cDNA clone derived from a blood-borne non-A,non-B viral hepatitis genome.” Science 244:359-362Crofts, N., C. K. Aitken, & J. M. Kaldor (1999). “The force of numbers: why hepatitis C isspreading among Australian injecting drug users while HIV is not.” Medical Journal ofAustralia 170 (5): 220-221Deeks, S. G., M. Smith, M. Holodiny, & J. O. Kahn (1997). “HIV-1 protea se inhibitors: areview for clinicians.” JAMA 277: 145-153Des Jarlais, D. C., et al (1995). “Maintaining low HIV seroprevalence in populations ofinjecting drug users.” Journal of the American Medical Association 274: 1226-1231Des Jarlais, D. C., et al (1996). “HIV incidence among injecting drug users in New YorkCity syring-exchange programmes.” Lancet 348: 987-991Drucker, E., P. Lurie, A. Wodak, & P. Alcabes (1998). “Measuring harm reduction: theeffects of needle and syringe exchange programs and methadone maintenance on theecology of HIV.” AIDS 12 (Supp. A): S217-S230Feachem, R. G. A. (1995). Valuing the Past…Investing in the Future: Evaluation of theNational HIV/AIDS Strategy 1993-94 to 1995-96. Australian Government PublishingService, CanberraFriedman, S. R., et al (1997). “Sociometric risk networks and risks for HIV infection.”American Journal of Public Health 87 (8): 1289-1296Gallo, J., et al (1985). “Fungal endopthalm itis in narcotic abusers.” The Medical Journal ofAustralia 142: 386-388Glanz, A., C. Byrne, & P. Jackson (1989). “Role of community pharmacies in prevention ofAIDS among injecting drug misusers: findings of a survey in England and Wales.” BritishMedical Journal 299: 1076-1079Goldberg, D., Burns, S. Taylor, A., Cameron, S., Hargreaves, D. & Hutchinson, S. (2001)“Trends in HCV prevalence among injecting drug users in Glasgow and Edinburgh during
24the era of needle/syringe exchange.” Scandinavian Journal of Infectious Diseases 33 (6):457-461Goldste in, A. C linton suppo rts needle ex change s but not funding. Washington Post. April21, 1998: A1Hagan, H., et al (1991). “The incidence of HBV infection and syringe exchange programs.”JAMA 266: 1646-1647Hagan, H., et a l (1993). “An inte rvie w study of pa rticipa nts in the Ta coma, Washington,syringe exchange.” Addiction 88: 1694-1695Hagan, H, D. C. Des Jarlais, S. R. Friedman, D. Purchase, & M. J. Alter (1995). “Reducedrisk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringeexchange program.” American Journal of Public Health 85: 1531-1537Harris, L. A. (1997). American Bar Association Report on Endorsing Needle Exchange.August 1997Hay, G & M. McKeganey (2001). “The attendance pattern of clients at a Scottish needleexchange.” Addiction 96 (2): 259-266He imer,R. K., & M. Lopes (1994). “Needle ex change in Ne w Ha ve n re duces HIV risks,promotes entry into drug treatment, and does not create new drug injectors.” JAMA271:1825-1826Heimer, R. K., et al (1994). “Three years of needle exchange in New Haven: what have welearned?” AIDS and Public Policy Journal 9:59-74He imer, R , K. Khoshnood, F. B. Ja riwa la, B. Dunca n, & Y. Ha rima (1996). “He pa titis inused syringes: the limits of sensitivity of techniques to detect HBV DNA, HCV RNA, andantibodies to HB core and HCV antigens.” Journal of Infectious Diseases 173: 997-1000Heimer, R. et al (1998). “Syringe use and reuse: effects of syringe exchange programs infour cities.” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology18 (Supp. 1): S37-S44Hellinger, F. K. (1992). “Forecasts of the costs of medical care for persons with HIV:1992-1995.” Inquiry 29: 356Holtgrave, D. R., & S. D. Pinkerton (1997). “Updates of cost of illness and quality of lifeestimates for use in economic evaluations of HIV prevention programs.” Journal ofAcquired Immune Deficiency Syndromes and Human Retrovirology 16: 54-62Hope, V. D., et al (2001). “Prevalence of hepatitis C among injection drug users inEngland and Wales: is harm reduction working?” American Journal of Public Health 91:38-42Hunter, G. M., et al (2000). “Measuring injecting risk behaviour in the second decade ofharm reduction: a survey of injecting drug users in England.” Addiction 95(9): 1351-1361Hurley, S. F., D. J. Jolley, & J. M. Kaldor (1997). “Effectiveness of needle-ex changeprogrammes for prevention of HIV infection.” Lancet 349: 1797-1800Hutchinson, S. J., A. Taylor, D. J. Goldberg, & L Gruer (2000). “Factors associated withinjecting risk behaviour among serial community-wide samples of injecting drug users in
Page 1 and 2: Effective Interventions UnitEVALUAT
Page 3 and 4: iABSTRACTThree hundred and sixty in
Page 5 and 6: 2diagnosed cases of HIV infected in
Page 7 and 8: 4and is so ld in poo rly so luble b
Page 9 and 10: 6CHAPTER 2 METHODOLOGYAims & Object
Page 11 and 12: 8CHAPTER 3 RESULTSStudy Group Chara
Page 13 and 14: 10more than any other drug also inj
Page 15 and 16: 12Table 3.5. Reasons for using curr
Page 17 and 18: 14The next most common eye problem
Page 19 and 20: 16That’s what I learnt from my ma
Page 21 and 22: 18s imply re turn to the needle ex
Page 23 and 24: 20rise in the numbe r o f visits is
Page 25: 22proposed to amend the misuse of d
Page 29 and 30: 26O live r, K. J., S. R . Friedman,
Page 31 and 32: APPENDIX B: Structured Questionnair
Page 33 and 34: US ING THE C ITRIC AC ID S ACHETS22
Page 35 and 36: 37. In the last 3 months, approxima
Page 37: APPENDIX D: C itric Acid SachetSour

Evaluation Of The Provision Of Single Use Citric Acid Sachets To ...

Create successful ePaper yourself

Delete template?

Save as template?